Signal from the log
Undecimal Bio
18 M$ · Seed · Biotech
Undecimal Bio, issue d'Eleven Therapeutics, développe des ARN interférents (siRNA), des molécules qui éteignent un gène, pour des organes autres que le foie, où la plupart des siRNA actuels restent cantonnés. La source n'a pas pu être ouverte.
Spotted
Announced on , logged by the watch of 12 October 2026.
- Operation
- Funding round
- Announced amount
- 18 M$
- Stage
- Seed
- Sector
- Biotech
What the log says
Editorial note, in French
Repérée par la collecte. Personne ne l'a encore instruite.
The investors
Led by IQ Capital , 4BIO Capital , with Verve Ventures , Harel Tech , Entree Capital , Kerna Ventures , Saras Capital
Provenance
Source endpoints,eu-startups,pulse2
Logged on 12 October 2026
Description Written in French during the watch run. Based on the headline as relayed by the source, without reading the issuer's press release.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Spotted The collection saw this operation and logged it. Nobody has processed it yet, so what is shown is still an automatic reading of the source headline.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.